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Poster Session II S369capacity of MultiStem (Athersys, Inc), a commercial hMAPC
product, was first evaluated in vitro in a MLC of purified mouse den-
dritic and T cells. MultiStem inhibited mouse T-cell proliferation
in a reproducible, dose dependent fashion not observed with human
dermal fibroblasts. This effect was associated with reduced T cell ac-
tivation and inflammatory cytokine secretion and robust increases in
the concentrations of PGE2 and TGFb in cell culture supernatants.
Importantly, MultiStem had no effect on the generation CTL ac-
tivity in vitro. Similar findings were observed in vivo when Multi-
Stem was delivered in the context of allo-BMT using C57BL/6
and B6D2F1 mice as donors and recipients, respectively. Tail vein
injection ofMultiStem onDay +1 (D1) and +4 (D4) resulted in sig-
nificant reductions in splenic T cell expansion and in numbers of
TNFa and IFNg-producingCD4+ andCD8+ cells at D10 compared
to untreated allo controls. These findings were associated with re-
ductions in 1) D10 serum levels of TNFa and IFNg, 2) D10 intesti-
nal and hepatic inflammation and 3) systemicGVHDasmeasured by
survival and clinical score. Suppression of systemic GVHD was ob-
served in a dose dependent manner. Biodistribution studies using
bioluminescence and cryo-imaging showed that MultiStem
tracked from the lung and into the abdominal organs (liver and
spleen) within the first 4 days after injection. When GVL effects
were tested, the administration of MultiStem resulted in superior
leukemia free survival; MultiStem treated mice had less GVHD
but effectively eradicated tumor challenge. Collectively, these data
provide critical information regarding the biodistribution and regu-
latory capacity of human MultiStem in established models of
GVHD. Mechanistic studies are ongoing, which we anticipate will
be useful in optimizing the dose and schedule of MultiStem in on-
going, first-in-human clinical trials following allogeneic BMT.448
SEVERE DENTAL CARIES IN PATIENTS WITH ORAL CHRONIC GRAFT-
VERSUS-HOST DISEASE
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Objective:The oral cavity is one of themost frequently affected sites
by cGVHD following allogeneic hematopoietic cell transplantation
(alloHCT), and can be a significant source of patient morbidity due
to bothmucosal and salivary gland involvement. The development of
dental decay is a potentially devastating oral complication that has
only rarely been reported in the transplantation literature. The pur-
pose of this study was to comprehensively characterize a cohort of
patients with cGVHD that subsequently developed extensive dental
caries.
Methods: A retrospective case-record review was conducted for pa-
tients who had undergone alloHCT at Dana-Farber/Brigham and
Women’s Cancer Center between 1990 and 2010 and developed
cGVHD-associated rampant dental decay. All patients underwent
dental evaluations before and after alloHCT that consisted of
a soft and hard tissue examination and dental radiographs. Caries di-
agnosed from the pre-alloHCT evaluation were treated definitively
such that all patients were considered free of caries at the time of ad-
mission for HCT.
Results: A total of 21 patients were identified with a median time of
cGVHDonset of 5.4months (range 2.2-18.5) post-alloHCT. All pa-
tients were diagnosed with oral cGVHD, with 90% demonstrating
mucosal involvement, and 95% with salivary gland involvement.
Post-alloHCT dental evaluation was performed at a median of 22
months (range 4-81) after alloHCT. when ten patients were diag-
nosed with gross caries and eight patients presented four or more af-
fected teeth. Cervical and interproximal patterns of dental caries
were frequently diagnosed. The proportion of patients with gross,
one surface, and greater than one surface caries, categorized as 0,
1-3, or $4, were significantly higher post-alloHCT compared to
pre-alloHCT with at least 50% of patients experiencing an increase.
Conclusions: Patients with oral cGVHD, who were free of caries at
the time of transplantation, developed extensive areas of cervical de-
cay in amedian time of less than two years post-alloHCT. This is the
first comprehensive characterization of this severe late complication
of alloHCT and oral cGVHD. Greater awareness on the part oftransplant oncologists and dentists as well asmore aggressive preven-
tive measures are warranted, as well as prospective studies to better
elucidate the incidence of this complication, identify risk factors,
and evaluate the effectiveness of preventive interventions.449
IN VIVO REFLECTANCE CONFOCAL MICROSCOPY IN THE EARLY DIAGNO-
SIS OF ACUTE CUTANEOUS GRAFT-VERSUS-HOST DISEASE: A PILOT
STUDY
Corbin, J.M., MacDonald, A., Purdy, K.S., Webb, A., Pasternak, S.,
Couban, S., Langley, R.G. Dalhousie University, Halifax, NS, Canada
Background: Graft-versus-host disease (GVHD) is a common and
potentially life-threatening complication of allogeneic hematopoi-
etic stem cell transplantation. The diagnosis of cutaneous GVHD
can be challenging, as it is based on clinical presentation, which often
simulates other processes. Early recognition and treatment are es-
sential to reduce the associated morbidity and mortality. Reflectance
confocal microscopy (RCM) is a high-resolution, noninvasive tech-
nique that may facilitate a timely diagnosis and prompt institution
of treatment.
Objective: We sought to describe the features of acute cutaneous
GVHD under RCM and to correlate these with the histopathologi-
cal findings.
Methods: Patients were recruited prospectively to undergo clinical
and RCM examination. A total of 19 patients were enrolled, five of
whom developed acute cutaneous GVHD following an allogeneic
hematopoietic stem cell transplant. RCM images from these five
cases were examined and the key confocal features were compared
to histopathological findings.
Results:OnRCMexamination, features of acute cutaneousGVHD,
such as apoptotic keratinocytes, inflammatory cell infiltration and in-
terface dermatitis, were identified and were shown to correlate well
with histopathological findings.
Limitations: The open-label, unblinded nature of this study allows
for potential observer bias and the small sample size may not reflect
the findings in a larger population. The sensitivity and specificity of
RCM in this population remain to be determined.
Conclusion: The findings support further examination of the use of
RCM in the rapid, bedside diagnosis of acute cutaneous GVHD.450
SIGNIFICANT ADVERSE EFFECTS ASSOCIATED WITH SIROLIMUS/TACRO-
LIMUS GVHD PROPHYLAXIS REGIMEN (SIRO-tac) IN ALLOGENEIC HEM-
ATOPOEITIC STEM CELL TRANSPLANT (alloHSCT) PATIENTS (pts): A
SINGLE INSTITUTION EXPERIENCE
Nathan, S., Maciejewski, J.J., Rich, E.S., Gregory, S.A., Schultz, K.,
Fung, H.C. Rush University Medical Center, Chicago, IL
Background: On account of the increased transplant related mor-
bidity and mortality with the use of methotrexate (MTX) based im-
munosuppressive therapy we adopted a new policy in GVHD
prophylaxis using a combination of tacrolimus and sirolimus abort-
ing the use ofMTX.We report the adverse effects that were noted in
our patients who underwent a related or un-related AlloHSCT
transplantation.
Patients and Methods: Data from 46 consecutive AlloHSCT pts
over a 2 year period were reviewed. 39 pts who received siro-tac
with or without ATG were identified. Demographics, indication
for transplantation, type of donor, conditioning regimen (CR),
GVHD prophylaxis associated complications were identified and
collected.
Results: 46 pts underwent an alloHSCT at our institution from
2009-11. 39 (84.78%) pts (average age 44 yrs, range 20-65 yrs) re-
ceived Siro-tac with or without ATG and all without MTX. 21
(53.84%) pts were male and 18 (46.15%) pts female. Indications
for transplant included relapsed non-Hodgkin lymphoma, Hodgkin
lymphoma, acute myelogenous leukemia, acute and chronic lympho-
cytic leukemia, myelodysplastic syndrome and myelofibrosis. 15
(46.15%) pts received a myeloablative CR. 14 pts had an unrelated
